Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions

Area of Science:

• Hepatology and Gastroenterology
• Metabolic Disorders
• Microbiome Research

Background:

• Non-alcoholic steatohepatitis (NASH) is a severe form of Non-alcoholic fatty liver disease (NAFLD), potentially leading to cirrhosis or liver cancer.
• Rising prevalence and complex pathogenesis involving microbiome and genetics present significant health challenges.

Purpose of the Study:

• To review the increasing prevalence of NASH.
• To explore the role of microbiome and genetics in NASH development.
• To discuss diagnostic challenges and emerging therapeutic strategies for NASH.

Main Methods:

• Literature review focusing on recent advancements in NASH research.
• Analysis of diagnostic limitations, including biopsy accessibility and insurance coverage issues.
• Evaluation of current and novel treatment approaches, including lifestyle modifications and pharmacological interventions.

Main Results:

• Diagnostic challenges persist, with liver biopsy being impractical for widespread screening, especially in developing nations.
• Lifestyle modifications are crucial but face adherence issues; bariatric interventions show promise but have limited access.
• Emerging drug classes in Phase II/III trials demonstrate potential for reducing liver fat and fibrosis with good tolerability.

Conclusions:

• NASH management requires innovative diagnostic tools and accessible treatments.
• Further research and well-designed studies are essential to validate new therapies and improve patient outcomes.
• Addressing diagnostic and treatment accessibility barriers is critical for global NASH control.